Downregulation of miR-221 enhances the sensitivity of human oral squamous cell carcinoma cells to Adriamycin through upregulation of TIMP3 expression

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Dan ChenYu Chen

Abstract

Aberrantly expressed microRNAs (miRNAs) are involved in oral tumorigenesis since they can alter the expression of proteins involved in cancer progression. It remains unclear whether miRNA-221 influences the resistance of human oral squamous cell carcinoma cells to Adriamycin. We therefore investigated the role of miR-221 in the sensitivity of oral squamous cell carcinoma cells to chemotherapy. Tca8113 and UM2 cells were treated with different concentrations of Adriamycin. Quantitative real-time PCR (qRT-PCR) revealed miR-221 upregulation after Adriamycin treatment of Tca8113 and UM2 cells. By using miR-221 inhibitor mimics, we found that depleting cells of miR-221 increases the sensitivity of the cells to Adriamycin. The expression of tissue inhibitor of metalloproteinase-3 (TIMP3), a target of miR-221, was decreased in cells treated with Adriamycin. TIMP3 depletion reversed the effect of a miR-221 inhibitor mimics on cell survival rates and apoptosis. Together, these results reveal that silencing of miR-221 enhances the sensitivity of human oral squamous cell carcinoma cells to Adriamycin through upregulation of TIMP3 expression.

References

Sep 17, 2004·Nature·Victor Ambros
Dec 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Nadia FelliCesare Peschle
Dec 22, 2007·Journal of Dental Research·S Choi, J N Myers
Jun 23, 2009·Cancer Chemotherapy and Pharmacology·Ozlem Darcansoy IşeriUfuk Gündüz
Jan 14, 2011·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Chun-Ju YangShu-Chun Lin
May 3, 2013·PloS One·Rounak NassirpourMin-Jean Yin
May 6, 2014·Oral and Maxillofacial Surgery Clinics of North America·Ahmed EidMark E Wong
May 8, 2014·BioMed Research International·Radosław JanuchowskiMaciej Zabel
Jul 11, 2014·Breast Cancer Research and Treatment·Yifang WeiJian Zhang
May 7, 2015·The Laryngoscope·Seda Salman YilmazMustafa Ozen
Jul 7, 2015·Life Sciences·Weifeng WangChangjun Lin

❮ Previous
Next ❯

Citations

Oct 25, 2017·Cancer Biomarkers : Section a of Disease Markers·Qi-Cai LiJiang Wu
Dec 17, 2017·Oncotarget·Yong-Jian WangYuan-Lin Zheng
Oct 4, 2019·Oncology Letters·Chuan Fang, Yadong Li
May 6, 2017·Angiogenesis·Judy R van BeijnumArjan W Griffioen
Dec 17, 2016·Cancer Biomarkers : Section a of Disease Markers·Fan ChenShun-E Yang
Dec 26, 2016·Archives of Dermatological Research·Olivera StojadinovicMarjana Tomic-Canic
Jul 31, 2019·Therapeutic Advances in Medical Oncology·Chun-Wen SuShun-Fa Yang
Mar 27, 2021·Frontiers in Molecular Biosciences·Zhu-Jun LawHui Poh Goh
Apr 4, 2021·International Journal of Molecular Sciences·Kumar RishabhAjaikumar B Kunnumakkara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis